Evidence map›Paper›PMID 29507048›Full record

ArticleGenetics2018

A Bayesian Framework for Generalized Linear Mixed Modeling Identifies New Candidate Loci for Late-Onset Alzheimer's Disease.

Xulong Wang, Vivek M Philip, Guruprasad Ananda, Charles C White, Ankit Malhotra, Paul J Michalski, Krishna R Murthy Karuturi, Sumana R Chintalapudi, Casey Acklin, Michael Sasner and 4 more

Abstract read
In one paragraph

Article in Genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Protein Kinase A in neurological disorders.Journal of neurodevelopmental disorders · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xulong WangThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609.
Vivek M PhilipThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609.
Guruprasad AnandaThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06032.
Charles C WhiteBroad Institute, Cambridge, Massachusetts 02142.
Ankit MalhotraThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06032.
Paul J MichalskiThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06032.
Krishna R Murthy KaruturiThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06032.
Sumana R ChintalapudiThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609.
Casey AcklinThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609.
Michael SasnerThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois 60612.
Philip L De JagerBroad Institute, Cambridge, Massachusetts 02142.
Gareth R HowellThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609 gareth.howell@jax.org greg.carter@jax.org.
Gregory W CarterThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine 04609 gareth.howell@jax.org greg.carter@jax.org.ORCID 0000-0002-2834-8186

Funding

The IU/JAX Alzheimer's Disease Precision Models Center: Rat F344U54AG054345 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Paul Richard Territo · 2016 to 2026
$95.6M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Risk Factors, Pathology, and Clinical Expressions of ADRF1AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2014 to 2014
$6.0M
Exploring the Role of the Brain Transcriptome in Cognitive DeclineR01AG036836 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DE JAGER, PHILIP L · 2011 to 2014
$2.9M
NIA NIH HHS P30 AG010161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG036836NIA NIH HHS RF1 AG015819NIA NIH HHS U01 AG046152NIA NIH HHS U54 AG054345
6 · The paper itself

Abstract

Recent technical and methodological advances have greatly enhanced genome-wide association studies (GWAS). The advent of low-cost, whole-genome sequencing facilitates high-resolution variant identification, and the development of linear mixed models (LMM) allows improved identification of putatively causal variants. While essential for correcting false positive associations due to sample relatedness and population stratification, LMMs have commonly been restricted to quantitative variables. However, phenotypic traits in association studies are often categorical, coded as binary case-control or ordered variables describing disease stages. To address these issues, we have devised a method for genomic association studies that implements a generalized LMM (GLMM) in a Bayesian framework, called

Indexed as

Bayes TheoremGenetic Predisposition to DiseaseLinear ModelsQuantitative Trait LociAge of OnsetAlgorithmsAlzheimer DiseaseAnimalsGenome-Wide Association StudyHumansMarkov ChainsMiceModels, BiologicalMonte Carlo MethodWhole Genome SequencingAlzheimer’s diseasegenome-wide associationwhole-genome sequencing

Identifiers

PMID29507048
PMCPMC5937180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.